Although further studies in additional CLL cell lines with different genetic backgrounds would be required to validate these findings, our results are in line with observations made in ex vivo studies and clinical trials where del(17p)/TP53 mutations are still a marker for less sensitivity and shorter OS in ibrutinib treated patients.45, 46. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.